Table 3.
Relation analysis between MCRPE resistance to the other six antimicrobial groups and their pathogenicity.
| Antimicrobial group | Pathogenicity | Resistant | Susceptible | p-value |
|---|---|---|---|---|
| Aminoglycosides | Non-pathogenic | 9 | 4 | 0.15 |
| Pathogenic | 7 | 12 | ||
| Fluoroquinolones | Non-pathogenic | 7 | 6 | 0.28 |
| Pathogenic | 6 | 13 | ||
| Tetracyclines | Non-pathogenic | 11 | 2 | 1.00 |
| Pathogenic | 17 | 2 | ||
| Nitrofurazones | Non-pathogenic | 3 | 10 | 1.00 |
| Pathogenic | 4 | 15 | ||
| Phenicols | Non-pathogenic | 9 | 4 | 1.00 |
| Pathogenic | 12 | 7 | ||
| Sulfonamides | Non-pathogenic | 7 | 6 | 1.00 |
| Pathogenic | 11 | 8 |
Aminoglycosides: amikacin, gentamicin, and tobramycin; fluoroquinolones: enrofloxacin and marbofloxacin; tetracyclines: tetracycline; nitrofurazones: nitrofurantoin; phenicols: chloramphenicol; sulfonamides: trimetroprim/sulfamethoxazole; pathogenic: ETEC, ETEC–EHEC; non-pathogenic: negative for virulence genes.